Trial · NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
NCT07340164, Phase 2, Recruiting, Yonsei University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy. Trials, record NCT07340164. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07340164
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
- NCT number
- NCT07340164
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 116 participants, estimated
- Lead sponsor
- Yonsei University
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent, Ovarian Cancer (OvCa)
- Interventions
- Trastzumab Deruxtecan, Bevacizumab, Platinum Based Chemotherapy
- First posted
- 2026-01-14
- Last updated
- 2026-04-20
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) in HER2 IHC 1+/2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the time from the date of randomization until first documentation of disease progression, as determined by investigator assessment based on RECIST 1.1, or death due to any cause, whichever occurs first. |
| Secondary | Progression Free Survival (PFS) in HER2 IHC 2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the time from the date of randomization until first documentation of disease progression, as determined by investigator assessment based on RECIST 1.1, or death due to any cause, whichever occurs first |
| Secondary | Objective Response Rate (ORR) by investigator in HER2 2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1 |
| Secondary | Objective Response Rate (ORR) by investigator in HER2 1+/2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of either complete response (CR) or partial response (PR), as investigator assessment based on RECIST 1.1 |
| Secondary | Disease control rate (DCR) by investigator in HER2 2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . SD must be achieved at ≥ 7 weeks after randomization to be considered best overall response. |
| Secondary | Disease control rate (DCR) by investigator in HER2 1+/2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . SD must be achieved at ≥ 7 weeks after randomization to be considered best overall response. |
| Secondary | Clinical benefit rate (CBR) by investigator in HER2 2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . (duration of SD ≥ 23 weeks after randomization) |
| Secondary | Clinical benefit rate (CBR) by investigator in HER2 1+/2+/3+ population | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Defined as the proportion of patients who have best overall response of CR, PR, or stable disease (SD) by investigator assessment per RECIST 1.1 . (duration of SD ≥ 23 weeks after randomization) |
| Secondary | Duration of Response Rate (DoR) by investigator in HER2 2+/3+ population | From the time of first documentation of CR or PR until the time of first documentation of subsequent PD or death from any cause, whichever came first, assessed up to 5 years. | Measured from the time of initial response until documented tumor progression. |
| Secondary | Duration of Response Rate (DoR) by investigator in HER2 1+/2+/3+ population | From the time of first documentation of CR or PR until the time of first documentation of subsequent PD or death from any cause, whichever came first, assessed up to 5 years. | Measured from the time of initial response until documented tumor progression. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07340164
GET https://conductscience.org/api/trials/v1/NCT07340164/registered